Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Therapeutic Targeting Of Cell Cycle Checkpoint Aberrations In Pancreatic Cancer: Personalised Medicine In Action
Funder
National Health and Medical Research Council
Funding Amount
$634,354.00
Summary
Less than 5% of people with pancreatic cancer (PC) survive 5 years, and the odds of patients beating this disease have remained unchanged for 50 years. Consequently, there is an urgent need to develop novel treatment approaches for this highly aggressive cancer. Our study aims to define novel therapeutic strategies for PC utilising specific anti-proliferative therapies and a personalised “companion biomarker” directed strategy.
Transient Tissue ‘priming’ Via FAK Inhibition To Impair Pancreatic Cancer Progression And Improve Sensitivity To Gemcitabine/Abraxane
Funder
National Health and Medical Research Council
Funding Amount
$643,848.00
Summary
The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.
Achieving Targeted Delivery Of Drugs To Uterine Muscle In Women For The Prevention Of Preterm Labour
Funder
National Health and Medical Research Council
Funding Amount
$469,008.00
Summary
We have patented liposomes targeted to the uterus, which enable us to deliver drugs specifically to the muscle cells of the uterus, increasing safety. The liposomes can be loaded with drugs that either block or promote contractions, creating a versatile drug delivery system that could treat premature labour or postpartum haemorrhage which are major clinical problems. We seek support to demonstrate their effectiveness in mouse and primate models of preterm labour prior to human studies.
A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
The critical role of the class III histone deacetylase SIRT2 in stabilizing N-Myc oncoprotein. Cancer is the commonest cause of death from disease in children. Neuroblastoma is the commonest solid tumor in early childhood. This project will investigate the critical roles of SIRT2 protein in increasing the expression of N-Myc oncoprotein and consequently inducing neuroblastoma, and SIRT2 inhibitors as anticancer agents.
Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0775587
Funder
Australian Research Council
Funding Amount
$532,000.00
Summary
Correlating Genomics and Proteomics for Systems Biology: integrating the '-omics'. Acquisition of the infrastructure requested will maintain and extend the expertise developed by researchers in NSW and will allow retention and attraction of leading researchers who can contribute to understanding how genes and proteins interact in the development of the organism - the central focus of systems biology. The enhancement of the facility will allow a better understanding of biomolecular interactions ....Correlating Genomics and Proteomics for Systems Biology: integrating the '-omics'. Acquisition of the infrastructure requested will maintain and extend the expertise developed by researchers in NSW and will allow retention and attraction of leading researchers who can contribute to understanding how genes and proteins interact in the development of the organism - the central focus of systems biology. The enhancement of the facility will allow a better understanding of biomolecular interactions in health and disease, providing both community and national benefits. The focus of this LIEF application is to provide infrastructure platforms for the study of the systems biology of organisms and additional capacity by the facility for the expected increased demand for this technology in this new area. Read moreRead less
Multilevel selection and the integrity of mitochondrial DNA. This project aims to investigate the evolutionary conundrum of how and why organelles remain asexual. The widespread occurrence of sexual reproduction suggests that sex is beneficial to organisms. Yet we all carry an ancient genome that never had sex, the mitochondrial genome (mtDNA). Theory predicts that mtDNA should no longer exist, because without sex it accumulates deleterious mutations and cannot accumulate beneficial ones. Yet mt ....Multilevel selection and the integrity of mitochondrial DNA. This project aims to investigate the evolutionary conundrum of how and why organelles remain asexual. The widespread occurrence of sexual reproduction suggests that sex is beneficial to organisms. Yet we all carry an ancient genome that never had sex, the mitochondrial genome (mtDNA). Theory predicts that mtDNA should no longer exist, because without sex it accumulates deleterious mutations and cannot accumulate beneficial ones. Yet mtDNA does not suffer mutational meltdown and is shown to adapt. This project will explain how, proposing that the combination of two traits, uniparental inheritance and multiple genomes per cell, make up for the lack of sex. This project expects to provide an explanation for the evolutionary question of what keeps mitochondria healthy, important as mitochondria affect ageing and health.Read moreRead less